activins has been researched along with Ectopic Ossification in 18 studies
Activins: Activins are produced in the pituitary, gonads, and other tissues. By acting locally, they stimulate pituitary FSH secretion and have diverse effects on cell differentiation and embryonic development. Activins are glycoproteins that are hetero- or homodimers of INHIBIN-BETA SUBUNITS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although inflammation is known to trigger HO in FOP, the role of FOP-ACVR1A on inflammatory cells remains to be elucidated." | 1.72 | Recapitulation of pro-inflammatory signature of monocytes with ACVR1A mutation using FOP patient-derived iPSCs. ( Jin, Y; Kamakura, T; Kawai, S; Maekawa, H; Matsuda, S; Nagata, S; Nishio, M; Niwa, A; Saito, MK; Toguchida, J; Yoshitomi, H, 2022) |
| "Palovarotene pretreatment did not reduce FAPs' skeletogenic potential, indicating that efficacy requires chronic administration." | 1.48 | Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity. ( Devarakonda, PM; Goldhamer, DJ; Lees-Shepard, JB; Nicholas, SE; Schneider, MJ; Stoessel, SJ; Yamamoto, M, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (61.11) | 24.3611 |
| 2020's | 7 (38.89) | 2.80 |
| Authors | Studies |
|---|---|
| Meng, X | 1 |
| Wang, H | 2 |
| Hao, J | 2 |
| Yamamoto, M | 2 |
| Stoessel, SJ | 2 |
| Yamamoto, S | 1 |
| Goldhamer, DJ | 2 |
| Maekawa, H | 1 |
| Jin, Y | 1 |
| Nishio, M | 1 |
| Kawai, S | 1 |
| Nagata, S | 1 |
| Kamakura, T | 1 |
| Yoshitomi, H | 1 |
| Niwa, A | 1 |
| Saito, MK | 1 |
| Matsuda, S | 1 |
| Toguchida, J | 1 |
| Schoenmaker, T | 1 |
| Zwaak, J | 1 |
| Loos, BG | 1 |
| Volckmann, R | 1 |
| Koster, J | 1 |
| Eekhoff, EMW | 1 |
| de Vries, TJ | 1 |
| Hwang, C | 1 |
| Pagani, CA | 1 |
| Das, N | 2 |
| Marini, S | 1 |
| Huber, AK | 1 |
| Xie, L | 2 |
| Jimenez, J | 1 |
| Brydges, S | 1 |
| Lim, WK | 1 |
| Nannuru, KC | 1 |
| Murphy, AJ | 2 |
| Economides, AN | 3 |
| Hatsell, SJ | 3 |
| Levi, B | 1 |
| Xie, C | 1 |
| Jiang, W | 1 |
| Lacroix, JJ | 1 |
| Luo, Y | 1 |
| Mundy, C | 1 |
| Yao, L | 1 |
| Sinha, S | 1 |
| Chung, J | 1 |
| Rux, D | 1 |
| Catheline, SE | 1 |
| Koyama, E | 1 |
| Qin, L | 1 |
| Pacifici, M | 1 |
| Alessi Wolken, DM | 1 |
| Idone, V | 2 |
| Yu, PB | 1 |
| Upadhyay, J | 1 |
| Huang, L | 1 |
| Stewart, RC | 1 |
| Lyon, MC | 1 |
| Palmer, K | 1 |
| Rajamani, S | 1 |
| Graul, C | 1 |
| Lobo, M | 1 |
| Wellman, TJ | 1 |
| Soares, EJ | 1 |
| Silva, MD | 1 |
| Hesterman, J | 1 |
| Wang, L | 1 |
| Wen, X | 1 |
| Qian, X | 1 |
| Nannuru, K | 1 |
| Shore, EM | 2 |
| Pignolo, RJ | 2 |
| Kaplan, FS | 2 |
| LaBonty, M | 1 |
| Pray, N | 1 |
| Yelick, PC | 1 |
| Lees-Shepard, JB | 1 |
| Nicholas, SE | 1 |
| Devarakonda, PM | 1 |
| Schneider, MJ | 1 |
| Lin, H | 1 |
| Shi, F | 1 |
| Gao, J | 1 |
| Hua, P | 1 |
| Valer, JA | 1 |
| Sánchez-de-Diego, C | 1 |
| Gámez, B | 1 |
| Mishina, Y | 1 |
| Rosa, JL | 1 |
| Ventura, F | 1 |
| Katagiri, T | 1 |
| Barruet, E | 1 |
| Morales, BM | 1 |
| Lwin, W | 1 |
| White, MP | 1 |
| Theodoris, CV | 1 |
| Kim, H | 1 |
| Urrutia, A | 1 |
| Wong, SA | 1 |
| Srivastava, D | 1 |
| Hsiao, EC | 1 |
| de Gorter, DJ | 1 |
| Jankipersadsing, V | 1 |
| Ten Dijke, P | 1 |
5 reviews available for activins and Ectopic Ossification
| Article | Year |
|---|---|
Recent progress in drug development for fibrodysplasia ossificans progressiva.
Topics: Activins; Bone Morphogenetic Proteins; Drug Development; Humans; Ligands; Mutation; Myositis Ossific | 2022 |
The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva.
Topics: Activin Receptors, Type I; Activins; Humans; Mutation; Myositis Ossificans; Ossification, Heterotopi | 2018 |
The role of Activin A in fibrodysplasia ossificans progressiva: a prominent mediator.
Topics: Activins; Animals; Humans; Myositis Ossificans; Ossification, Heterotopic; Signal Transduction | 2019 |
Granting immunity to FOP and catching heterotopic ossification in the Act.
Topics: Activin Receptors, Type I; Activins; Animals; Bone Morphogenetic Proteins; Humans; Immunity, Innate; | 2016 |
[Fibrodysplasia ossificans progressiva and osteoimmunology].
Topics: Activins; Animals; Bone Morphogenetic Proteins; Genetic Predisposition to Disease; Humans; Mutation; | 2016 |
13 other studies available for activins and Ectopic Ossification
| Article | Year |
|---|---|
Overexpression of Wild-Type ACVR1 in Fibrodysplasia Ossificans Progressiva Mice Rescues Perinatal Lethality and Inhibits Heterotopic Ossification.
Topics: Activin Receptors, Type I; Activins; Animals; Humans; Mice; Mice, Transgenic; Mutation; Myositis Oss | 2022 |
Recapitulation of pro-inflammatory signature of monocytes with ACVR1A mutation using FOP patient-derived iPSCs.
Topics: Activin Receptors, Type I; Activins; Animals; Doxycycline; Humans; Inflammation; Lipopolysaccharides | 2022 |
Transcriptomic Differences Underlying the Activin-A Induced Large Osteoclast Formation in Both Healthy Control and Fibrodysplasia Ossificans Progressiva Osteoclasts.
Topics: Activin Receptors, Type I; Activins; Humans; Mutation; Myositis Ossificans; Ossification, Heterotopi | 2023 |
Activin A does not drive post-traumatic heterotopic ossification.
Topics: Activin Receptors, Type I; Activins; Animals; Humans; Mice; Myositis Ossificans; Ossification, Heter | 2020 |
Insight into Molecular Mechanism for Activin A-Induced Bone Morphogenetic Protein Signaling.
Topics: Activin Receptors, Type I; Activin Receptors, Type II; Activins; Animals; Bone Morphogenetic Protein | 2020 |
Activin A promotes the development of acquired heterotopic ossification and is an effective target for disease attenuation in mice.
Topics: Activins; Animals; Chondrogenesis; Mice; Myositis Ossificans; Ossification, Heterotopic; Osteogenesi | 2021 |
The Expansion of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva Is Activin A-Dependent.
Topics: Activins; Animals; Magnetic Resonance Imaging; Mice; Myositis Ossificans; Ossification, Heterotopic; | 2017 |
Activin A amplifies dysregulated BMP signaling and induces chondro-osseous differentiation of primary connective tissue progenitor cells in patients with fibrodysplasia ossificans progressiva (FOP).
Topics: Activins; Bone Morphogenetic Protein 4; Bone Morphogenetic Proteins; Cell Differentiation; Cells, Cu | 2018 |
Injury of Adult Zebrafish Expressing Acvr1l
Topics: Activin Receptors, Type I; Activins; Animal Fins; Animals; Animals, Genetically Modified; Cardiotoxi | 2018 |
Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity.
Topics: Activin Receptors, Type I; Activins; Animals; Bone and Bones; Cell Differentiation; Chondrogenesis; | 2018 |
Inhibition of phosphatidylinositol 3-kinase α (PI3Kα) prevents heterotopic ossification.
Topics: Activin Receptors, Type I; Activins; Animals; Bone Morphogenetic Proteins; Class I Phosphatidylinosi | 2019 |
The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling.
Topics: Activin Receptors, Type I; Activins; Bone Morphogenetic Protein 4; Cell Differentiation; Cell Line; | 2016 |
Deregulated bone morphogenetic protein receptor signaling underlies fibrodysplasia ossificans progressiva.
Topics: Activin Receptors, Type I; Activins; Animals; Bone Morphogenetic Protein Receptors; Bone Morphogenet | 2012 |